FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1910946589> ?p ?o ?g. }

• W1910946589 endingPage "iv317" @default.
• W1910946589 startingPage "iv317" @default.
• W1910946589 abstract "ABSTRACT Aim: There is some evidence that participating in clinical trials may be associated with better survival in cancer patients. We wished to investigate whether outcome for patients with epithelial ovarian cancer (EOC) treated on a clinical trial was associated with a better outcome at our institution. Methods: Patients with EOC treated on three UK MRC first-line clinical trials: ICON-5, ICON-7 and SCOTROC-4, between 2002 and 2008 were each matched with individuals who received 1st line chemotherapy out with a clinical trial (“non-trial”). Cases were matched for age ( 65years), FIGO stage ( 2C), histology (serous, clear cell, endometroid or other), surgical status (sub-optimal or optimal debulking) and chemotherapy received 1st line (carboplatin and taxol or carboplatin alone). All patients were World Health Organisation (WHO) performance status 0 or 1. Data were analysed using StatsDirect Ltd. 2013 England. Results: Thirty patients treated on clinical trials were matched with 30 patients who received treatment “off-trial”. There were 4 patients in each group with early stage disease. The median progression free survival for patients treated on a trial was 26.4 months, compared with 24.6 months for patients who received 1st line chemotherapy out with a trial. The difference between groups was not significant (Log Rank test, HR 0.85, 95% CI: 0.47 to 1.54, p = 0.6). The median overall survival (OS) for patients treated on a trial was 64.3 months compared with 62 months for “non-trial” patients. The difference in OS between both groups was not significant (Log Rank test, HR 0.86, 95%CI: 0.46 to 1.63, p = 0.6). Conclusions: Data from our institution, a tertiary referral centre active in clinical trials, shows a good outcome for patients with advanced ovarian cancer regardless of whether they received 1st line chemotherapy on a clinical trial. Our data compares favourably with survival data from ICON-5 (median OS 44.1 months) and SCOTROC-4 (median OS 34 months). Disclosure: All authors have declared no conflicts of interest." @default.
• W1910946589 created "2016-06-24" @default.
• W1910946589 creator A5010310569 @default.
• W1910946589 creator A5020983677 @default.
• W1910946589 creator A5023247842 @default.
• W1910946589 creator A5037722704 @default.
• W1910946589 creator A5044719549 @default.
• W1910946589 creator A5046835966 @default.
• W1910946589 date "2014-09-01" @default.
• W1910946589 modified "2023-10-17" @default.
• W1910946589 title "Clinical Trial Participation and Outcomes in Ovarian Cancer: a Case Control Study" @default.
• W1910946589 doi "https://doi.org/10.1093/annonc/mdu338.40" @default.
• W1910946589 hasPublicationYear "2014" @default.
• W1910946589 type Work @default.
• W1910946589 sameAs 1910946589 @default.
• W1910946589 citedByCount "1" @default.
• W1910946589 countsByYear W19109465892023 @default.
• W1910946589 crossrefType "journal-article" @default.
• W1910946589 hasAuthorship W1910946589A5010310569 @default.
• W1910946589 hasAuthorship W1910946589A5020983677 @default.
• W1910946589 hasAuthorship W1910946589A5023247842 @default.
• W1910946589 hasAuthorship W1910946589A5037722704 @default.
• W1910946589 hasAuthorship W1910946589A5044719549 @default.
• W1910946589 hasAuthorship W1910946589A5046835966 @default.
• W1910946589 hasBestOaLocation W19109465891 @default.
• W1910946589 hasConcept C121608353 @default.
• W1910946589 hasConcept C126322002 @default.
• W1910946589 hasConcept C143998085 @default.
• W1910946589 hasConcept C2780427987 @default.
• W1910946589 hasConcept C29456083 @default.
• W1910946589 hasConcept C535046627 @default.
• W1910946589 hasConcept C71924100 @default.
• W1910946589 hasConceptScore W1910946589C121608353 @default.
• W1910946589 hasConceptScore W1910946589C126322002 @default.
• W1910946589 hasConceptScore W1910946589C143998085 @default.
• W1910946589 hasConceptScore W1910946589C2780427987 @default.
• W1910946589 hasConceptScore W1910946589C29456083 @default.
• W1910946589 hasConceptScore W1910946589C535046627 @default.
• W1910946589 hasConceptScore W1910946589C71924100 @default.
• W1910946589 hasLocation W19109465891 @default.
• W1910946589 hasOpenAccess W1910946589 @default.
• W1910946589 hasPrimaryLocation W19109465891 @default.
• W1910946589 hasRelatedWork W1523310174 @default.
• W1910946589 hasRelatedWork W2017484494 @default.
• W1910946589 hasRelatedWork W2056064246 @default.
• W1910946589 hasRelatedWork W2169394819 @default.
• W1910946589 hasRelatedWork W2589428929 @default.
• W1910946589 hasRelatedWork W2996702193 @default.
• W1910946589 hasRelatedWork W3047265282 @default.
• W1910946589 hasRelatedWork W4211208004 @default.
• W1910946589 hasRelatedWork W567261565 @default.
• W1910946589 hasRelatedWork W2186113122 @default.
• W1910946589 hasVolume "25" @default.
• W1910946589 isParatext "false" @default.
• W1910946589 isRetracted "false" @default.
• W1910946589 magId "1910946589" @default.
• W1910946589 workType "article" @default.